Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix
Primary Purpose
Peripheral Artery Disease
Status
Unknown status
Phase
Phase 4
Locations
Italy
Study Type
Interventional
Intervention
Freeway PTA
Lutonix PTA
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Artery Disease
Eligibility Criteria
Inclusion Criteria:
- age>18 years
- angiographic stenosis>50% or occlusion of one below-knee vessel
Exclusion Criteria:
- allergy to Paclitaxel
- contraindication for combined antiplatelet treatment
- life expectancy <1 year
- hypersensitivity or contraindication to one of the study drugs
- lack of consent
- need for amputation
Sites / Locations
- Cardiovascular Department, Ospedale S.DonatoRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Freeway
Lutonix
Arm Description
angioplasty with Freeway drug-eluting balloon
angioplasty with Lutonix drug-eluting balloon
Outcomes
Primary Outcome Measures
number of events of angiographic binary restenosis
number of events of angiographic binary restenosis
Secondary Outcome Measures
number of events of target lesion revascularization
number of events of target lesion revascularization
number of events of death
number of events of death
frequency of major amputation
frequency of major amputation
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02279784
Brief Title
Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Unknown status
Study Start Date
October 2014 (undefined)
Primary Completion Date
December 2015 (Anticipated)
Study Completion Date
October 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ospedale San Donato
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to compare in patients with critical limb ischemia the efficacy of angioplasty with different paclitaxel-eluting balloon devices for below-the-knee lesions in terms of restenosis.
Detailed Description
Two devices will be evaluated: the Lutonix and the Freeway paclitaxel eluting balloons. A post-hoc analysis will compare the results with the historical data from DEBATE-BTK (NCT01558505).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Artery Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
160 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Freeway
Arm Type
Experimental
Arm Description
angioplasty with Freeway drug-eluting balloon
Arm Title
Lutonix
Arm Type
Experimental
Arm Description
angioplasty with Lutonix drug-eluting balloon
Intervention Type
Device
Intervention Name(s)
Freeway PTA
Intervention Description
angioplasty with Freeway drug-eluting balloon
Intervention Type
Device
Intervention Name(s)
Lutonix PTA
Intervention Description
angioplasty with Lutonix drug-eluting balloon
Primary Outcome Measure Information:
Title
number of events of angiographic binary restenosis
Description
number of events of angiographic binary restenosis
Time Frame
12 months
Secondary Outcome Measure Information:
Title
number of events of target lesion revascularization
Description
number of events of target lesion revascularization
Time Frame
12 months
Title
number of events of death
Description
number of events of death
Time Frame
12 months
Title
frequency of major amputation
Description
frequency of major amputation
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age>18 years
angiographic stenosis>50% or occlusion of one below-knee vessel
Exclusion Criteria:
allergy to Paclitaxel
contraindication for combined antiplatelet treatment
life expectancy <1 year
hypersensitivity or contraindication to one of the study drugs
lack of consent
need for amputation
Facility Information:
Facility Name
Cardiovascular Department, Ospedale S.Donato
City
Arezzo
State/Province
AR
ZIP/Postal Code
52100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francesco Liistro, MD
Email
francescoliistro@hotmail.com
First Name & Middle Initial & Last Name & Degree
Leonardo Bolognese, MD, FESC
First Name & Middle Initial & Last Name & Degree
Giovanni Falsini, MD
First Name & Middle Initial & Last Name & Degree
Paolo Angioli, MD
First Name & Middle Initial & Last Name & Degree
Kenneth Ducci, MD
First Name & Middle Initial & Last Name & Degree
Francesco Liistro, MD
First Name & Middle Initial & Last Name & Degree
Simone Grotti, MD
12. IPD Sharing Statement
Learn more about this trial
Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix
We'll reach out to this number within 24 hrs